Business Wire

I-COM

30.9.2020 05:03:53 CEST | Business Wire | Press release

Share
Harm Reduction Policies Essential to Prevent Cancer, Say I-Com and MEPs

I-Com, the Institute for Competitiveness, yesterday hosted a landmark roundtable in the context of Europe’s Beating Cancer Plan, summarised here , bringing together policymakers from across the political spectrum, academics and scientists to present the findings of their study on best practices to beat cancer.

During the roundtable, the discussion analysed best practices and successes of harm reduction policies across Europe. Enabling citizens to live healthier lifestyles by making less risky products accessible, such as vaping devices for smokers, by conducting education and awareness campaigns about responsible alcohol consumption and by building infrastructure promoting physical activity are examples of the core ideas driving the evidence-based approach behind harm reduction policy. During the public consultations on the Beating Cancer Plan, 20% of submissions highlighted harm reduction’s potential role.

Dolors Montserrat, Hosting MEP and a member of the Special Cancer Committee, said:

“I want to thank I-Com for the study just published that highlights how prevention policies aimed at reducing risk factors have a lot of potential to help Europe beat cancer. The Special Cancer Committee and the European Parliament welcome the study findings aimed to contribute to the future actions orientation of the Beating Cancer Plan. Our wish is for the Parliament to play a key role in developing the Plan in effective and fruitful coordination with the European Commission.”

Commenting on the roundtable, Stefano da Empoli, President of I-Com, said:

“We were delighted to present our recommendations on how harm reduction can support the prevention of cancer. It is now clear that public health experts, policymakers and academics all support the inclusion of harm reduction policies to help prevent cancer and mitigate the harm caused by tobacco, alcohol and unhealthy diets. Legislators must, at all times, keep patients at the forefront of their minds. Now is the time to embrace harm reduction.”

Margratis Schinas, European Commissioner for Promoting the European Way of Life, said:

“Our aim for the Plan is that cancer should no longer mean chances
fading away, dropping out from projects, or stigmatisation.
Instead, one day, cancer shall mean accessible treatment, recovery
and, therefore, life opportunities for all affected people.
And this is possible. Up to 40% of cancers can be prevented.”

I-Com’s recommended best practices in minimising the harms caused by alcohol, tobacco and nutrition, include reducing the availability of alcohol, increasing the availability of smokeless tobacco products and building infrastructure promoting physical activity.

ABOUT I-COM

The Institute for Competitiveness (I-Com) is an Italian independent think tank based in Rome and Brussels, founded in 2005 by a group of scholars, professionals and managers. I-Com aims at influencing the public debate at the national, European and international level, analysing the most important drivers for competitiveness and growth.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye